Abbott Navitor (Aortic Valve Transcatheter Implantation System)

2023: Start of implantation

On January 17, 2023, Abbott announced the start of the next generation transcatheter aortic valve implantation (TAVI) system implantation. Navitor is designed for patients with severe aortic stenosis who are at high or extreme risk during open heart surgery.

Aortic stenosis is, as noted, one of the most frequent pathologies of the valve apparatus, occupying the top lines in the list of causes of disability and mortality in the population in Russia, the USA and Europe. There are no conservative methods of therapy for aortic stenosis, the only effective method is aortic valve prosthetics. The Navitor system offers less invasive treatment options for some of the most common and serious heart diseases.

Implantation of Abbott aortic valve begins

The solution is equipped with a unique NaviSeal tissue cuff that reduces or completely eliminates reverse blood flow bypassing the valve - the so-called paraclavular leak. In addition, the new device is the only self-opening TAVI system with leaflets inside the native valve: this design allows improved access to coronary arteries to facilitate future procedures for the treatment of coronary heart disease. The system also provides excellent hemodynamics.

The Navitor TAVI procedure uses the FlexNav delivery system. It is suitable for patients with different anatomical features and narrow vessels for stable, predictable and accurate valve delivery and installation.

Navitor is the first TAVI system to provide optimal hemodynamics for valves of all sizes, as well as preserving opportunities for the treatment of diseases throughout life, which is an important factor for doctors and patients when choosing a treatment option, "said Michael Dale, Senior Vice President Abbott.[1]

2021: Announcement of the aortic valve implantation system

In late May 2021, Abbott announced the release of Navitor's new transcatheter aortic valve implantation (TAVI) system. According to a press release, this latest generation TAVI system has been approved by European regulatory authorities to treat patients with severe aortic stenosis who are at high or extreme risk for surgery.

Navitor uses Abbott's FlexNav delivery system with a unique design providing a less invasive alternative to surgical aortic valve replacement. The new system features a NaviSeal tissue cuff that works like a normal heart valve, reducing or eliminating the back flow of blood bypassing the valve (paraclavular leakage).

Abbott unveils Abbott Navitor aortic valve implantation system

Abbott introduced Navitor as the only self-expanding TAVI system with intra-ring flaps and large framework cells. They should improve access to critical coronary arteries and facilitate future intracoronary interventions for the treatment of coronary heart disease or myocardial infarction.

The innovative Navitor valve design combined with the FlexNav delivery system optimizes and simplifies TAVI procedures for surgeon physicians, allowing for more precise valve placement and improved efficiency. All this helps patients quickly return to a full and healthy life, "said Michael Dale, senior vice president of Abbott's heart structural elements division, in a press release. - The new TAVI system expands our portfolio of offerings for minimally invasive treatments for cardiovascular disease, providing new opportunities and improving therapy for life-threatening heart disease.[2]

Notes